1. Dube SR, Felitti VJ, Dong M, Chapman DP, Giles WH, Anda RF. Childhood abuse, neglect, and household dysfunction and the risk of illicit drug use: the adverse childhood experiences study. Pediatrics. 2003;111(3):564–572. http://pediatrics.aappublications.org/content/pediatrics/111/3/564.full.pdf. Accessed February 2, 2018.
2. Felitti VJ, Anda RF, Nordenberg D, et al. Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults: the adverse childhood experiences (ACE) study. Am J Prev Med. 1998;14(4):245–258. In: https://www.cambridgema.gov/CDD/Projects/Planning/~/media/328D3B716A24449D8504357BD3865949.ashx. Accessed January 25, 2019.
3. The Role of Adverse Childhood Experiences in Substance Misuse and Related Behavioral Health Problems. SAMHSA’s Center for the Application of Prevention Technologies; 2018. https://www.cambridgema.gov/CDD/Projects/Planning/~/media/328D3B716A24449D8504357BD3865949.ashx. Accessed January 25, 2019.
4. Comorbidity: Addiction & Other Mental Illnesses. NIDA Research Report Series. NIH Publication Number 10-5771. North Bethesda, MD: National Institutes of Health, National Institute on Drug Abuse; 2010. https://www.drugabuse.gov/sites/default/files/rrcomorbidity.pdf. Accessed February 6, 2018.
5. Mandavia A, Robinson GGN, Bradley B, Ressler KJ, Powers A. Exposure to childhood abuse and later substance use: indirect effects of emotion dysregulation and exposure to trauma. J Trauma. 2016;29(5):422–429. doi:10.1002/jts.22131.
6. Mirhashem R, Allen HC, Adams ZW, Van Stolk-Cooke K, Legrand A, Price M. The intervening role of urgency on the association between childhood maltreatment, PTSD, and substance-related problems. Addict Behav. 2017;69:98–103. doi:10.1016/j.addbeh.2017.02.012.
7. Centers for Disease Control & Prevention. Wide-ranging online data for epidemiologic research (WONDER). https://wonder.cdc.gov/. Published 2016. Accessed December 1, 2017.
8. Opioid overdose crisis. National Institute on Drug Abuse website. https://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis. Updated January 2019. Accessed August 10, 2019.
9. Ciccarone D. The triple wave epidemic: supply and demand drivers of the US opioid overdose crisis. Int J Drug Policy. Published online February 1, 2019. doi:10.1016/j.drugpo.2019.01.010.
10. Ghertner R, Groves L. The Opioid Crisis and Economic Opportunity: Geographic and Economic Trends. ASPE Research Brief. Washington, DC: US Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation; 2018. https://aspe.hhs.gov/system/files/pdf/259261/ASPEEconomicOpportunityOpioidCrisis.pdf. Accessed January 25, 2019.
11. Addiction science. National Institute on Drug Abuse website. https://www.drugabuse.gov/related-topics/addiction-science. Updated July 2015. Accessed August 10, 2019.
12. Whelan PJ, Remski K. Buprenorphine vs methadone treatment: a review of evidence in both developed and developing worlds. J Neurosci Rural Pract. 2012;3(1):45–50. doi:10.4103/0976-3147.91934.
13. Nielsen S, Larance B, Lintzeris N. Opioid agonist treatment for patients with dependence on prescription opioids. J Am Med Assoc. 2017;317(9):967–968. doi:10.1001/jama.2017.0001.
14. Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169(3):137–145. doi:10.7326/M17-3107.
15. Larney S. Does opioid substitution treatment in prisons reduce injecting-related HIV risk behaviours? A systematic review. Addiction. 2010;105(2):216–223. doi:10.1111/j.1360-0443.2009.02826.x.
16. Hedrich D, Alves P, Farrell M, Stöver H, Møller L, Mayet S. The effectiveness of opioid maintenance treatment in prison settings: a systematic review. Addiction. 2012;107(3):501–517. doi:10.1111/j.1360-0443.2011.03676.x.
17. Lappalainen L, Nolan S, Dobrer S, et al. Dose-response relationship between methadone dose and adherence to antiretroviral therapy among HIV-positive persons who use illicit opioids. Addiction. 2015;110(8):1330–1339. doi:10.1111/add.12970.
18. Magura S, Lee JD, Hershberger J, et al. Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial. Drug Alcohol Depend. 2009;99(1–3):222–230 doi:10.1016/j.drugalcdep.2008.08.006.
19. Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis. 2012;31(3):207–225. doi:10.1080/10550887.2012.694598.
20. Roman PM, Abraham AJ, Knudsen HK. Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation. Addict Behav. 2011;36(6):584–589. doi:10.1016/j.addbeh.2011.01.032.
21. Abraham AJ, Knudsen HK, Rieckmann T, Roman PM. Disparities in access to physicians and medications for the treatment of substance use disorders between publicly and privately funded treatment programs in the United States. J Stud Alcohol Drugs. 2013;74(2):258–265. doi:10.15288/jsad.2013.74.258.
22. Potter JS, Marino EN, Hillhouse MP, et al. Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START). J Stud Alcohol Drugs. 2013;74(4):605–613.
23. Substance Abuse and Mental Health Services Administration. TIP 63: Medications for Opioid Use Disorder for Healthcare and Addiction Professionals, Policymakers, Patients, and Families. HHS Publication No. (SMA) 19-5063FULLDOC. Rockville, MD: SAMHSA; 2018. https://store.samhsa.gov/product/TIP-63-Medications-for-Opioid-Use-Disorder-Full-Document-Including-Executive-Summary-and-Parts-1-5-/SMA18-5063FULLDOC. Accessed July 9, 2018.
24. World Health Organization, United Nations Office on Drugs and Crime, Joint United Nations Programme on HIV/AIDS. Substitution Maintenance Therapy in the Management of Opioid Dependence and HIV/AIDS Prevention. WHO/UNODC/UNAIDS position paper. Geneva, Switzerland: WHO; 2004. https://www.who.int/substance_abuse/publications/en/PositionPaper_English.pdf. Accessed August 10, 2019.
25. Sharma A, O’Grady KE, Kelly SM, Gryczynski J, Mitchell SG, Schwartz RP. Pharmacotherapy for opioid dependence in jails and prisons: research review update and future directions. Subst Abuse Rehabil. 2016;7:27–40. doi:10.2147/SAR.S81602.
26. Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for oral testimony before the House Committee on Energy and Commerce Hearing, “Federal Efforts to Combat the Opioid Crisis: A Status Update on CARA and Other Initiatives” [news release]. Silver Spring, MD: Food and Drug Administration; October 25, 2017. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm582031.htm. Accessed August 10, 2019.
27. US Department of Health and Human Services (HHS), Office of the Surgeon General. Facing Addiction in America: The Surgeon General’s Spotlight on Opioids. Washington, DC: HHS; September 2018. https://addiction.surgeongeneral.gov/sites/default/files/Spotlight-on-Opioids_09192018.pdf. Accessed January 16, 2019.
28. Leshner AI, Mancher M, eds. Medications for Opioid Use Disorder Save Lives. Washington, DC: National Academies Press; 2019. doi:10.17226/25310.
29. Lopez G. 2016 opioid overdoses killed more Americans than Iraq and Vietnam. Vox. July 7, 2017. www.vox.com/policy-and-politics/2017/7/7/15925488/opioid-epidemic-deaths-2016. Accessed August 10, 2019.
30. Dowell D, Arias E, Kochanek K, et al. Contribution of opioid-involved poisoning to the change in life expectancy in the United States, 2000–2015. JAMA. 2017;318(11):1065–1067. doi:10.1001/JAMA.2017.9308.
31. Salihu HM, Wilson RE, King LM, Marty PJ, Whiteman VE. Socio-ecological model as a framework for overcoming barriers and challenges in randomized control trials in minority and underserved communities. Int J MCH AIDS. 2015;3(1):85–95. http://www.ncbi.nlm.nih.gov/pubmed/27621990. Accessed April 27, 2018.
32. Montano DE, Kasprzyk D. Theory of reasoned action, theory of planned behavior, and the integrated behavioral model. In: Glanz K, Rimer BK, Viswanath K, eds. Health Behavior and Health Education: Theory, Research, and Practice. 4th ed. San Francisco, CA: Jossey-Bass; 2008:67–96.
33. Waldorf D, Orlick M, Reinarman C. Morphine Maintenance: The Shreveport Clinic 1919–1923. Washington, DC: Drug Abuse Council; 1974.
34. Webb v United States, 249 US 96 (1919).
35. White WL. Slaying the Dragon: The History of Addiction Treatment & Recovery in America. Bloomington, IL: Chestnut; 1998.
36. Musto D, Ramos M. Notes on American history: a follow-up study of the New Haven morphine maintenance clinic of 1920. N Engl J Med. 1981;304(18):1071–1077.
37. America’s first drug-treatment prison revisited [transcript]. All Things Considered. National Public Radio. November 1, 2008. https://www.npr.org/templates/story/story.php?storyId=96437766. Accessed August 10, 2019.
38. Conversation with Jerome H. Jaffe. Addiction. 1999;94(1):13–30. doi:10.1080/09652149934143.
39. Addiction research: Jerome Jaffe, interviewed by Nancy Campbell for the Oral History of Substance Abuse Research project [transcript]. Published 1969. http://www.williamwhitepapers.com/pr/2013 Dr. Jerome Jaffe.pdf. Accessed January 26, 2019.
40. Courtwright DT. Dark Paradise: A History of Opiate Addiction. Cambridge, MA: Harvard University Press; 2001.
41. Campbell N, Olsen JP, Walden L. The Narcotic Farm: The Rise and Fall of America’s First Prison for Drug Addicts. New York, NY: Harry N Abrams Inc; 2008.
42. Massing M. The Fix. Los Angeles: University of California Press; 1998.
43. Clark C. The Recovery Revolution: The Battle over Addiction Treatment in the United States. New York, NY: Columbia University Press; 2017.
44. Doberteen L. Orange Handcuffs, Part of an (In)Complete Breakfast: Methadone’s Failure to Address Structural Inequalities in the Civil Rights Era [thesis]. New York, NY: Columbia University; 2015.
45. Shuster A. GI heroin addiction epidemic in Vietnam. New York Times. May 16, 1971. http://www.nytimes.com/1971/05/16/archives/gi-heroin-addiction-epidemic-in-vietnam-gi-heroin-addiction-is.html. Accessed August 10, 2019.
46. Drug wars: interview with Dr. Jerome Jaffe [edited transcript]. Frontline. PBS; 2000. https://www.pbs.org/wgbh/pages/frontline/shows/drugs/interviews/jaffe.html. Accessed February 8, 2018.
47. Jaffe JH, O’Keeffe C. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Depend. 2003;70(2):S3–S11. doi:10.1016/S0376-8716(03)00055-3.
48. Reuter P. Why has US drug policy changed so little over 30 years? Crime and Justice. 2013;42(1):75–140. doi:10.1086/670818.
49. Cherkis J. Nancy Reagan’s legacy includes support of abusive drug treatment for teens. Huffington Post. March 7, 2016. https://www.huffingtonpost.com/entry/nancy-reagan-drug-treatment-straight-inc_us_56ddda84e4b03a405679693e. Accessed August 10, 2019.
50. Drucker E. Failed drug policies in the United States and the future of AIDS: a perfect storm. J Public Heal Policy. 2012;33(3):309–316. http://www.jstor.org/stable/pdf/23253451.pdf. Accessed February 8, 2018.
51. Kohn H. Cowboy in the capital: drug czar Bill Bennett. Rolling Stone. November 2, 1989. https://www.rollingstone.com/politics/politics-news/cowboy-in-the-capital-drug-czar-bill-bennett-45472/. Accessed January 26, 2019.
52. Bennett W. National Drug Control Strategy. Washington, DC: Office of National Drug Control Policy; September 1989. https://www.ncjrs.gov/pdffiles1/ondcp/119466.pdf. Accessed January 26, 2019.
53. Bennett W, Walters JP. Bring back the war on drugs. Boston Globe. September 9, 2015. https://www.hudson.org/research/11585-bring-back-the-war-on-drugs. Accessed August 10, 2019.
54. Burns RM, Pacula RL, Bauhoff S, et al. Policies related to opioid agonist therapy for opioid use disorders: the evolution of state policies from 2004 to 2013. Subst Abus. 2016;37(1):63–69. doi:10.1080/08897077.2015.1080208.
55. Campbell ND, Lovell AM. The history of the development of buprenorphine as an addiction therapeutic. Ann N Y Acad Sci. 2012;1248(1):124–139. doi:10.1111/j.1749-6632.2011.06352.x.
56. Harper J. To grow market share, a drugmaker pitches its product to judges. Shots: Health News from NPR. National Public Radio. August 3, 2017. https://www.npr.org/sections/health-shots/2017/08/03/540029500/to-grow-market-share-a-drugmaker-pitches-its-product-to-judges. Accessed August 10, 2019.
57. Jackson H, Mandell K, Johnson K, Chatterjee D, Vanness DJ. Cost-effectiveness of injectable extended-release naltrexone compared with methadone maintenance and buprenorphine maintenance treatment for opioid dependence. Subst Abus. 2015;36(2):226–231. doi:10.1080/08897077.2015.1010031.
58. Lee JD, Nunes EV, Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309–318. doi:10.1016/S0140-6736(17)32812-X.
59. Tanum L, Solli KK, Latif Z-H, et al. The effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence. JAMA Psychiatry. 2017;74(12):1197–1205. doi:10.1001/jamapsychiatry.2017.3206.
60. Morgan JR, Schackman BR, Leff JA, Linas BP, Walley AY. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. J Subst Abuse Treat. 2018;85:90–96. doi:10.1016/j.jsat.2017.07.001.
61. Yokell MA, Zaller ND, Green TC, Rich JD. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. Curr Drug Abus Rev. 2011;4(1):28–41. https://www-ncbi-nlm-nih-gov.proxy.medlib.uits.iu.edu/pmc/articles/PMC3154701/pdf/nihms314965.pdf. Accessed October 24, 2017.
62. Khanna IK, Pillarisetti S. Buprenorphine: an attractive opioid with underutilized potential in treatment of chronic pain. J Pain Res. 2015;8:859–870. doi:10.2147/JPR.S85951.
63. Gaebel W, Zäske H, Cleveland HR, et al. Measuring the stigma of psychiatry and psychiatrists: development of a questionnaire. Eur Arch Psychiatry Clin Neurosci. 2011;261(Suppl 2):S119–123. doi:10.1007/s00406-011-0252-0.
64. Fatséas M, Auriacombe M. Why buprenorphine is so successful in treating opiate addiction in France. Curr Psychiatry Rep. 2007;9(5):358–364. doi:10.1007/s11920-007-0046-2.
65. Schedules of controlled substances: Rescheduling of buprenorphine from Schedule V to Schedule III. Fed. Regist. 2002;67(194):62354–62370. To be codified at 21 CFR §1308. https://www.govinfo.gov/content/pkg/FR-2002-10-07/pdf/02-25293.pdf. Accessed August 10, 2019.
66. Facher L. Nearly all doctors can freely prescribe opioids. Now a new movement aims to vastly deregulate an addiction treatment. STAT News. April 30, 2019. https://www.statnews.com/2019/04/30/loosen-restrictions-on-prescribing-buprenorphine-addiction-treatment. Accessed August 10, 2019.
67. Andraka-Christou B. America needs the TREAT Act: expanding access to effective medication for treating addiction. Health Matrix Clevel. 2016;26:309–362.
68. Pub L No. 109-56, 119 Stat 591 (2005). https://www.congress.gov/109/plaws/publ56/PLAW-109publ56.pdf. Accessed August 10, 2019.
69. Office of National Drug Control Policy Reauthorization Act of 2006, Pub L No. 109-469, 120 Stat 3502. https://www.congress.gov/109/plaws/publ469/PLAW-109publ469.htm. Accessed August 10, 2019.
70. Statement of Senator Orrin Hatch regarding the Office of National Drug Control Policy Reauthorization Act of 2006. Cong Rec Sen. 2006;152(135):S11703–S11706.
71. Vestal C. Waiting lists grow for medicine to fight opioid addiction. Huffington Post. February 11, 2016. http://www.huffingtonpost.com/entry/opioid-addiction-treatment_us_56bcb1a5e4b08ffac1241b63. Accessed August 10, 2019.
72. Schuman-Olivier Z, Connery H, Griffin ML, et al. Clinician beliefs and attitudes about buprenorphine/naloxone diversion. Am J Addict. 2013;22(6):574–580. doi:10.1111/j.1521-0391.2013.12024.x.
73. Johanson CE, Arfken CL, di Menza S, Schuster CR. Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians. Drug Alcohol Depend. 2012;120(1–3):190–195. doi:10.1016/j.drugalcdep.2011.07.019.
74. Genberg BL, Gillespie M, Schuster CR, et al. Prevalence and correlates of street-obtained buprenorphine use among current and former injectors in Baltimore, Maryland. Addict Behav. 2013;38(12):2868–2873. doi:10.1016/j.addbeh.2013.08.008.
75. Office Based Opioid Treatment Programs, S 398, 120th Gen Assem, 2nd Sess (In 2018). https://iga.in.gov/legislative/2018/bills/senate/398#document-dc532596. Accessed February 8, 2018.
76. Subramaniam G, Levy S, Sullivan MA. PCSS Guidance Topic: Treatment of Opioid-Dependent Adolescents and Young Adults Using Sublingual Buprenorphine. East Providence, RI: Providers’ Clinical Support System; 2013. https://30qkon2g8eif8wrj03zeh041-wpengine.netdna-ssl.com/wp-content/uploads/2014/03/PCSS-MATGuidanceTreatmentofOpioidDependantAdolescent-buprenorphine.SubramaniamLevy1.pdf. Accessed October 27, 2018.
77. Trial AR, Woody GE, Poole SA, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA. 2008;300(17):2003–2011.
78. Harper J. A drugmaker tries to cash in on the opioid epidemic, one state law at a time. Shots: Health News from NPR. National Public Radio. June 12, 2017.
79. Schwarz A. Michael Botticelli is a drug czar who knows addiction firsthand. New York Times. April 25, 2015. https://www.nytimes.com/2015/04/26/us/michael-botticelli-is-a-drug-czar-who-knows-addiction-firsthand.html. Accessed August 10, 2019.
80. Botticelli M. Remarks at: The Road Back from the Opioid Crisis: Lessons for State Leadership; September 17, 2015; Arlington, VA. https://obamawhitehouse.archives.gov/the-press-office/2015/09/17/remarks-ondcp-director-michael-botticelli. Accessed February 8, 2018.
81. Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies—tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063–2066. doi:10.1056/NEJMp1402780.
82. Brooklyn JR, Sigmon SC. Vermont hub-and-spoke model of care for opioid use disorder: development, implementation, and impact. J Addict Med. 2017;11(4):286–292. doi:10.1097/ADM.0000000000000310.
83. Comprehensive Addiction and Recovery Act, S 524, 114th Cong (2016). https://www.congress.gov/bill/114th-congress/senate-bill/524/text. Accessed February 8, 2018.
84. Fiscella K, Wakeman SE, Beletsky L. Buprenorphine deregulation and mainstreaming treatment for opioid use disorder: X the X waiver. JAMA Psychiatry. 2019;76(3):229–230. doi:10.1001/jamapsychiatry.2018.3685.
85. 21st Century Cures Act, HR 34, 114th Cong (2016). https://www.congress.gov/bill/114th-congress/house-bill/34/. Accessed February 8, 2018.
86. Trump budget doubles down on drug war [news release]. New York, NY: Drug Policy Alliance; February 12, 2018. http://www.drugpolicy.org/press-release/2018/02/trump-budget-doubles-down-drug-war. Accessed August 10, 2019.
87. The federal drug control budget: new rhetoric, same failed drug war [fact sheet]. New York, NY: Drug Policy Alliance; February 2015. https://www.drugpolicy.org/sites/default/files/DPA_Fact_sheet_Drug_War_Budget_Feb2015.pdf. Accessed August 10, 2019.
88. Christie C, Baker C, Cooper R, Kennedy PJ, Madras B, Bondi P. The president’s commission on combating drug addiction and the opioid crisis. https://www.whitehouse.gov/sites/whitehouse.gov/files/images/Final_Report_Draft_11-15-2017.pdf. Published November 2017. Accessed February 8, 2018.
89. Lopez G. Trump just signed a bipartisan bill to confront the opioid epidemic. Vox. October 24, 2018. https://www.vox.com/policy-and-politics/2018/9/28/17913938/trump-opioid-epidemic-congress-support-act-bill-law. Accessed August 10, 2019.
90. President Donald J. Trump is taking action on drug addiction and the opioid crisis [fact sheet]. Washington, DC: White House Briefings & Statements; October 26, 2017. https://www.whitehouse.gov/briefings-statements/president-donald-j-trump-taking-action-drug-addiction-opioid-crisis/. Accessed February 8, 2018.
91. Opioid treatment program directory. Substance Abuse and Mental Health Services Administration website. https://dpt2.samhsa.gov/treatment/directory.aspx. Accessed June 3, 2018.
92. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;(3):CD002209. doi:10.1002/14651858.CD002209.pub2.
93. Rosenblatt RA, Andrilla CHA, Catlin M, Larson EH. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Ann Fam Med. 2015;13(1):23–26. doi:10.1370/afm.1735.
94. Hansen H, Siegel C, Wanderling J, DiRocco D. Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City. Drug Alcohol Depend. 2016;164:14–21. doi:10.1016/j.drugalcdep.2016.03.028.
95. Lagisetty PA, Ross R, Bohnert A, Clay M, Maust DT. Buprenorphine treatment divide by race/ethnicity and payment. JAMA Psychiatry. Published online May 8, 2019. doi:10.1001/jamapsychiatry.2019.0876.
96. Stein BD, Dick AW, Sorbero M, et al. A population-based examination of trends and disparities in medication treatment for opioid use disorders among Medicaid enrollees. Subst Abus. 2018;39(4):419–425. doi:10.1080/08897077.2018.1449166.
97. Substance Abuse and Mental Health Services Administration. National Survey of Substance Abuse Treatment Services (N-SSATS): 2013. Data on Substance Abuse Treatment Facilities. BHSIS Series S-73, HHS Publication No. (SMA) 14-489. Rockville, MD: SAMHSA; 2014. https://www.samhsa.gov/data/sites/default/files/2013_N-SSATS/2013_N-SSATS_National_Survey_of_Substance_Abuse_Treatment_Services.pdf. Accessed February 8, 2018.
98. Wu L-T, Zhu H, Swartz MS. Treatment utilization among persons with opioid use disorder in the United States. Drug Alcohol Depend. 2016;169:117–127. doi:10.1016/j.drugalcdep.2016.10.015.
99. West SL, O’Neal KK. Project D.A.R.E. outcome effectiveness revisited. Am J Public Health. 2004;94(6):1027–1029.
100. Pagano ME, White WL, Kelly JF, Stout RL, Carter RR, Tonigan JS. The 10-year course of AA participation and long-term outcomes: a follow-up study of outpatient subjects in Project MATCH. Subst Abus. 2013;34(1):51–59. doi:10.1080/08897077.2012.691450.
101. Nielsen S, Larance B, Degenhardt L, Gowing L, Kehler C, Lintzeris N. Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database Syst Rev. 2016;(5):CD011117. doi:10.1002/14651858.CD011117.pub2.
102. Saloner B, Karthikeyan S, RC D, et al. Changes in substance abuse treatment use among individuals with opioid use disorders in the United States, 2004–2013. JAMA. 2015;314(14):1515–1517. doi:10.1001/jama.2015.10345.
103. Roman PM, Johnson JA. National Treatment Center Study Summary Report: Private Treatment Centers. Athens, GA: Institute for Behavioral Research; 2004. http://ntcs.uga.edu/reports/NTCS summary reports/NTCS Report No. 7.pdf. Accessed February 21, 2018.
104. Andraka-Christou B. What is treatment for opioid addiction in problem-solving courts? A study of 20 Indiana drug & veterans courts. Stanford J Civ Rights Civ Lib. 2017;13(2):189–254.
105. Substance abuse probation. 204 Pennsylvania Administrative Code §89.293. https://www.padisciplinaryboard.org/for-attorneys/rules/rule/7/disciplinary-board-rules-and-procedures. Accessed August 10, 2019.
106. Berge K, Sepalla M, Schipper A. Chemical dependency and the physician. Mayo Clin Proc. 2009;84(7):625–631. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2704134/. Accessed August 10, 2019.
107. Walters GD. Twelve reasons why we need to find alternatives to Alcoholics Anonymous. Addict Disord Their Treat. 2002;1(2):53–59. https://journals.lww.com/addictiondisorders/Abstract/2002/06000/Twelve_Reasons_Why_We_Need_to_Find_Alternatives_to.3.aspx. Accessed August 10, 2019.
108. Travis T. The Language of the Heart: A Cultural History of the Recovery Movement from Alcoholics Anonymous to Oprah Winfrey. Chapel Hill: University of North Carolina Press; 2009.
109. Whelan PJP, Marshall EJ, Ball DM, Humphreys K. The role of AA sponsors: a pilot study. Alcohol Alcohol. 2009;44(4):416–422. doi:10.1093/alcalc/agp014.
110. The twelve steps of Alcoholics Anonymous [service material]. New York, NY: Alcoholics Anonymous Publishing; 1981. https://www.aa.org/assets/en_US/smf-121_en.pdf. Updated August 2016. Accessed on August 10, 2019.
111. Tournier RE. Alcoholics Anonymous as treatment and as ideology. J Stud Alcohol. 1979;40(3):230–239.
112. Estimates of AA groups and members as of January 1, 2017 [service material]. New York, NY: AA World Services; 2017. https://www.aa.org/assets/en_US/smf-53_en.pdf. Updated March 2019. Accessed April 10, 2018.
113. Humphreys K, Wing S, McCarty D, et al. Self-help organizations for alcohol and drug problems: toward evidence-based practice and policy. J Subst Abuse Treat. 2004;26(3):151–158. doi:10.1016/S0740-5472(03)00212-5.
114. Kessler R, Mickelson K, Zhao S. Patterns and correlates of self-help group membership in the United States. Soc Policy. 1997;27(3):27–46. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.372.1885&rep=rep1&type=pdf. Accessed August 10, 2019.
115. Humphreys K. Circles of Recovery: Self-Help Organizations for Addictions. Cambridge, UK: Cambridge University Press; 2004.
116. Miller M. The relevance of twelve-step recovery in 21st century addiction medicine. ASAM Magazine [blog]. American Society of Addiction Medicine website. February 13, 2015.
117. Knudsen HK, Abraham AJ, Oser CB. National Treatment Center Study Project Report, Barriers to the Adoption of Pharmacotherapies in Publicly Funded Substance Abuse Treatment: Policy Barriers and Access to Physicians. Athens, GA: Institute for Behavioral Research; 2011. http://ntcs.uga.edu/reports/Medications in Publicly Funded Treatment.pdf. Accessed February 21, 2018.
118. Rieckmann TR, Kovas AE, McFarland BH, Abraham AJ. Counselor attitudes toward the use of buprenorphine in substance abuse treatment: a multi-level modeling approach. J Subst Abuse Treat. 2011;41(4):374–385. doi:10.1016/j.jsat.2011.05.005.
119. Knudsen HK, Ducharme LJ, Roman PM, Link T. Buprenorphine diffusion: the attitudes of substance abuse treatment counselors. J Subst Abuse Treat. 2005;29(2):95–106. doi:10.1016/j.jsat.2005.05.002.
120. Magura S, Rosenblum A. Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored. Mt Sinai J Med. 2001;68(1):62–74. http://www.ncbi.nlm.nih.gov/pubmed/11135508. Accessed February 9, 2018.
121. Clausen T, Anchersen K, Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend. 2008;94(1–3):151–157. doi:10.1016/j.drugalcdep.2007.11.003.
122. Gilman SM, Dermatis H, Galanter M. Methadone Anonymous: a 12-step program for methadone maintained heroin addicts. Subst Abus. 2001;22(4):247–256. doi:10.1080/08897070109511466.
123. Narcotics Anonymous and persons receiving medication-assisted treatment [pamphlet]. Chatsworth, CA: NA World Services Inc.; 2016. https://www.na.org/admin/include/spaw2/uploads/pdf/pr/2306_NA_PRMAT_1021.pdf. Accessed August 10, 2019.
124. Regarding methadone and other drug replacement programs. World Service Board of Trustees Bulletin #29. Van Nuys, CA: Narcotics Anonymous World Services; 1996. https://www.na.org/?ID=bulletins-bull29. Accessed February 9, 2018.
125. Suzuki J, Dodds T. Clinician recommendation of 12-step meeting attendance and discussion regarding disclosure of buprenorphine use among patients in office-based opioid treatment. Subst Abus. 2016;37(1):31–34. doi:10.1080/08897077.2015.1132292.
126. White WL, Campbell MD, Shea C, Hoffman HA, Crissman B, Dupont RL. Coparticipation in 12-step mutual aid groups and methadone maintenance treatment: a survey of 322 patients. J Groups Addict Recover. 2013;8(4):294–308. doi:10.1080/1556035X.2013.836872.
127. Monico LB, Gryczynski J, Mitchell SG, et al. Buprenorphine treatment and 12-step meeting attendance: conflicts, compatibilities, and patient outcomes. J Subst Abus Treat. 2015;57:89–95. doi:10.1016/j.jsat.2015.05.005.
128. Bentzley BS, Barth KS, Back SE, Book SW. Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes. J Subst Abuse Treat. 2015;52:48–57. doi:10.1016/j.jsat.2014.12.011.
129. Gibson A, Degenhardt L, Mattick RP, Ali R, White J, O’Brien S. Exposure to opioid maintenance treatment reduces long-term mortality. Addiction. 2008;103(3):462–468. doi:10.1111/j.1360-0443.2007.02090.x.
130. Parran TV, Adelman CA, Merkin B, et al. Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy. Drug Alcohol Depend. 2010;106(1):56–60. doi:10.1016/j.drugalcdep.2009.07.013.
131. Fiellin DA, Moore BA, Sullivan LE, et al. Long-term treatment with buprenorphine/naloxone in primary care: results at 2–5 years. Am J Addict. 2008;17(2):116–120. doi:10.1080/10550490701860971.
132. Potter JS, Dreifuss JA, Marino EN, et al. The multi-site prescription opioid addiction treatment study: 18-month outcomes. J Subst Abuse Treat. 2015;48(1):62–69. doi:10.1016/j.jsat.2014.07.009.
133. Poloméni P, Schwan R. Management of opioid addiction with buprenorphine: French history and current management. Int J Gen Med. 2014;7:143–148. doi:10.2147/IJGM.S53170.
134. White B. Dr. Vincent Dole (1913–2006) on methadone maintenance treatment. Selected Papers of William L. White. October 30, 2015. http://www.williamwhitepapers.com/blog/2015/10/dr-vincent-dole-1913-2006-on-methadone-maintenance-treatment.html. Accessed February 27, 2018.
135. Pisani E. Tilting at windmills and the evidence base on injecting drug use. Lancet. 2010;376(9737):226–227. doi:10.1016/S0140-6736(10)61132-4.
136. Hawk M, Coulter RWS, Egan JE, et al. Harm reduction principles for healthcare settings. Harm Reduct J. 2017;14(70). doi:10.1186/s12954-017-0196-4.
137. Kelly JF, Moos R. Dropout from 12-step self-help groups: prevalence, predictors, and counteracting treatment influences. J Subst Abuse Treat. 2003;24(3):241–250. doi:10.1016/S0740-5472(03)00021-7.
138. Kurtz E. Not-God: A History of Alcoholics Anonymous. San Francisco, CA: Harper & Row Publishers; 1979.
139. Rathert C, Wyrwich MD, Boren SA. Patient-centered care and outcomes: a systematic review of the literature. Med Care Res Rev. 2013;70(4):351–379. doi:10.1177/1077558712465774.
140. Humphreys K, Noke JM. The influence of posttreatment mutual help group participation on the friendship networks of substance abuse patients. Am J Community Psychol. 1997;25(1):1–16. doi:10.1023/A:1024613507082.
141. Atkins RG, Hawdon JE. Religiosity and participation in mutual-aid support groups for addiction. J Subst Abuse Treat. 2007;33(3):321–331. doi:10.1016/j.jsat.2007.07.001.
142. Zemore SE, Lui C, Mericle A, Hemberg J, Kaskutas LA. A longitudinal study of the comparative efficacy of Women for Sobriety, LifeRing, SMART Recovery, and 12-step groups for those with AUD. J Subst Abuse Treat. 2018;88:18–26. doi:10.1016/j.jsat.2018.02.004.
143. Fenster J. Characteristics of clinicians likely to refer clients to 12-step programs versus a diversity of post-treatment options. Drug Alcohol Depend. 2006;83(3):238–246. doi:10.1016/j.drugalcdep.2005.11.017.
144. Kelly JF, White WL. Broadening the base of addiction mutual-help organizations. J Groups Addict Recover. 2012;7(2–4):82–101. doi:10.1080/1556035X.2012.705646.
145. Auriacombe M, Denis CM, Beltran V, et al. 10-years outcome of methadone- and buprenorphine-maintained patients: mortality, quality of life and substance use. Drug Alcohol Depend. 2014;140:e8. doi:10.1016/j.drugalcdep.2014.02.043.
146. Evans E, Li L, Min J, et al. Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006–10. Addiction. 2015;110(6):996–1005. doi:10.1111/add.12863.
147. Marsden J, Stillwell G, Jones H, et al. Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A national prospective observational study in England. Addiction. 2017;112(8):1408–1418. doi:10.1111/add.13779.
148. Saxon AJ, Hser Y-I, Woody G, Ling W. Medication-assisted treatment for opioid addiction: methadone and buprenorphine. J Food Drug Anal. 2013;21(4):S69–S72. doi:10.1016/j.jfda.2013.09.037.
149. Substance Abuse and Mental Health Services Administration. National Survey of Substance Abuse Treatment Services (N-SSATS): 2016. Data on Substance Abuse Treatment Facilities. BHSIS Series S-93, HHS Publication No. (SMA) 17-5039. Rockville, MD: SAMHSA; 2017. https://wwwdasis.samhsa.gov/dasis2/nssats/2016_nssats_rpt.pdf. Accessed January 10, 2018.
150. Knudsen HK, Ducharme LJ, Roman PM, Link T. Buprenorphine diffusion: The attitudes of substance abuse treatment counselors. J Subst Abuse Treat. 2005;29(2):95–106. doi:10.1016/j.jsat.2005.05.002.
151. Rieckmann T, Daley M, Fuller BE, Thomas CP, McCarty D. Client and counselor attitudes toward the use of medications for treatment of opioid dependence. J Subst Abuse Treat. 2007;32(2):207–215. doi:10.1016/j.jsat.2006.09.002.
152. Abraham AJ, Rieckmann T, McNulty T, Kovas AE, Roman PM. Counselor attitudes toward the use of naltrexone in substance abuse treatment: A multi-level modeling approach. Addict Behav. 2011;36(6):576–583. doi:10.1016/j.addbeh.2011.01.030.
153. Cunningham CO, Sohler NL, McCoy K, Kunins HV. Attending physicians’ and residents’ attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital. Fam Med. 2006;38(5):336–340. https://fammedarchives.blob.core.windows.net/imagesandpdfs/fmhub/fm2006/May/Chinazo336.pdf. Accessed August 10, 2019.
154. Aletraris L, Edmond MB, Paino M, Fields D, Roman PM. Counselor training and attitudes toward pharmacotherapies for opioid use disorder. Subst Abus. 2016;37(1):47–53. doi:10.1080/08897077.2015.1062457.
155. Johnson RA, Lukens JM, Kole JW, Sisti DA. Views about responsibility for alcohol addiction and negative evaluations of naltrexone. Subst Abuse Treat Prev Policy. 2015;10(1):10. doi:10.1186/s13011-015-0004-7.
156. Keller DS, Dermatis H. Current status of professional training in the addictions. Subst Abus. 1999;20(3):123–140. doi.org/10.1080/08897079909511401.
157. Kerwin ME, Walker-Smith K, Kirby KC. Comparative analysis of state requirements for the training of substance abuse and mental health counselors. J Subst Abuse Treat. 2006;30(3):173–181. doi:10.1016/j.jsat.2005.11.004.
158. Mulvey KP, Hubbard S, Hayashi S. A national study of the substance abuse treatment workforce. J Subst Abus Treat. 2003;24(1):51–57. doi:10.1016/S0740-5472(02)00322-7.
159. Campbell TC, Catlin LA, Melchert TP. Alcohol and other drug abuse counselors’ attitudes and resources for integrating research and practice. J Drug Educ. 2003;33(3):307–323. doi:10.2190/VUHN-X36D-KH56-2P77.
160. Wendt DC, Gone JP. Complexities with group therapy facilitation in substance use disorder specialty treatment settings. J Subst Abuse Treat. 2018;88:9–17. doi:10.1016/J.JSAT.2018.02.002.
161. SAMHSA’s National Outcome Measure Domains. https://dhs.iowa.gov/sites/default/files/SAMHSA-National-Outcome-Measures_09-01-2011.pdf. Accessed February 5, 2019.
162. National Association of State Alcohol and Drug Abuse Directors. State Regulations on Substance Use Disorder Programs and Counselors: An Overview. Washington, DC: NASADAD; 2012. https://nasadad.org/wp-content/uploads/2010/12/State_Regulation_of_SUD_Programs_and_Counselors-7-26-13.pdf. Updated July 2013. Accessed August 10, 2019.
163. McCarty D, Braude L, Lyman DR, et al. Substance abuse intensive outpatient programs: assessing the evidence. Psychiatr Serv. 2014;65(6):718–726. doi:10.1176/appi.ps.201300249.
164. Reif S, George P, Braude L, et al. Residential treatment for individuals with substance use disorders: assessing the evidence. Psychiatr Serv. 2014;65(3):301–312. doi:10.1176/appi.ps.201300242.
165. Kourounis G, Richards BD, Kyprianou E, Symeonidou E, Malliori MM, Samartzis L. Opioid substitution therapy: lowering the treatment thresholds. Drug Alcohol Depend. 2016;161:1–8. doi:10.1016/j.drugalcdep.2015.12.021.
166. Carroll KM, Weiss RD. The role of behavioral interventions in buprenorphine maintenance treatment: a review. Am J Psychiatry. 2017;174(8):738–747. doi:10.1176/appi.ajp.2016.16070792.
167. Foreman ML, Jefferson T, de La Viez B, et al. Sharing the Dream: Is the ADA Accommodating All? Washington, DC: US Commission on Civil Rights; 2000. https://www.usccr.gov/pubs/ada/main.htm. Accessed January 28, 2019.
168. Medication Assisted Treatment for Opioid Use Disorders, 42 CFR §8. https://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&SID=0d945f6e5f6068b536698ccc72159bc8&r=PART&n=42y1.0.1.1.10#se42.1.8_112. Accessed August 10, 2019.
169. Medication-assisted treatment with methadone (MAT) laws [dataset]. Prescription Drug Abuse Policy System website. http://pdaps.org/datasets/medication-assisted-treatment-with-methadone-mat-laws. Published 2016. Accessed August 10, 2019.
170. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States. JAMA. 2016;315(15):1624–1645. doi:10.1001/jama.2016.1464.
171. O’Brien CP, McLellan AT. Myths about the treatment of addiction. Lancet. 1996;347(8996):237–240. doi:10.1016/S0140-6736(96)90409-2.
172. Indiana Code 12-23-18-5. http://iga.in.gov/legislative/laws/2019/ic/titles/012#12-23-18-5. Accessed August 10, 2019.
173. Silverman K, Wong CJ, Higgins ST, et al. Increasing opiate abstinence through voucher-based reinforcement therapy. Drug Alcohol Depend. 1996;41(2):157–165. doi:10.1016/0376-8716(96)01246-X.
174. Comer SD, Sullivan MA, Vosburg SK, et al. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction. 2010;105(4):709–718. doi:10.1111/j.1360-0443.2009.02843.x.
175. Zhang Z, Friedmann PD, Gerstein DR. Does retention matter? Treatment duration and improvement in drug use. Addiction. 2003;98(5):673–684. http://www.ncbi.nlm.nih.gov/pubmed/12751985. Accessed April 26, 2018.
176. Strike C, Millson M, Hopkins S, Smith C. What is low threshold methadone maintenance treatment? Int J Drug Policy. 2013;24(6):e51–e56. doi:10.1016/j.drugpo.2013.05.005.
177. Merrill JO, Jackson TR, Schulman BA, et al. Methadone medical maintenance in primary care: an implementation evaluation. J Gen Intern Med. 2005;20(4):344–349. doi:10.1111/j.1525-1497.2005.04028.x.
178. Andraka-Christou B, Capone MJ. A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in US office-based practices. Int J Drug Policy. 2018;54:9–17. doi:10.1016/j.drugpo.2017.11.021.
179. Addiction medicine. American Board of Preventive Medicine website. http://www.theabpm.org/become-certified/subspecialties/addiction-medicine. Accessed June 3, 2018.
180. Alderks CE. The CBHSQ Report: Trends in the Use of Methadone, Buprenorphine, and Extended-Release Naltrexone at Substance Abuse Treatment Facilities: 2003–2015 (Update). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2017. https://www.samhsa.gov/data/sites/default/files/report_3192/ShortReport-3192.pdf. Accessed January 23, 2018.
181. Joseph H, Stancliff S, Langrod J. Methadone maintenance treatment (MMT): a review of historical and clinical issues. Mt Sinai J Med. 2000;67(5–6):347–364. PMID:11064485.
182. D’Aunno T, Pollack HA, Frimpong JA, Wuchiett D. Evidence-based treatment for opioid disorders: a 23-year national study of methadone dose levels. J Subst Abuse Treat. 2014;47(4):245–250. doi:10.1016/j.jsat.2014.06.001.
183. Johnson RE, Chutuape M, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med. 2000;343(18):1290–1297. doi:10.1056/NEJM200011023431802.
184. Strain E, Bigelow GE, Liebson I, Stitzer ML. Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA. 1999;281(11):1000–1005. doi:10.1001/jama.281.11.1000.
185. Strain EC. Methadone dose during maintenance treatment. In: Strain EC, Stitzer ML, eds. The Treatment of Opioid Dependence. Baltimore, MD: Johns Hopkins University Press; 2006:89–118.
186. Donny EC, Walsh SL, Bigelow GE, Eissenberg T, Stitzer ML. High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans. Psychopharmacology (Berl). 2002;161(2):202–212. doi:10.1007/s00213-002-1027-0.
187. Bakalar N. Vital signs patterns: many fatal overdoses linked to methadone. Well (blog). New York Times. July 9, 2012. https://well.blogs.nytimes.com/2012/07/09/many-fatal-overdoses-linked-to-methadone. Accessed August 10, 2019.
188. Duffy P, Baldwin H. The nature of methadone diversion in England: a Merseyside case study. Harm Reduct J. 2012;9(1):3. doi:10.1186/1477-7517-9-3.
189. Johnson B, Richert T. Diversion of methadone and buprenorphine from opioid substitution treatment: the importance of patients’ attitudes and norms. J Subst Abuse Treat. 2015;54:50–55. doi:10.1016/j.jsat.2015.01.013.
190. Harris M, Rhodes T. Methadone diversion as a protective strategy: The harm reduction potential of “generous constraints.” Int J Drug Policy. 2013;24(6):e43–e50. doi:10.1016/j.drugpo.2012.10.003.
191. Barnett PG, Zaric GS, Brandeau ML. The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. Addiction. 2001;96(9):1267–1278. doi:10.1080/09652140120070328.
192. Byford S, Barrett B, Metrebian N, et al. Cost-effectiveness of injectable opioid treatment v. oral methadone for chronic heroin addiction. Br J Psychiatry. 2013;203(5):341–349. doi:10.1192/bjp.bp.112.111583.
193. Tolia VN, Murthy K, Bennett MM, et al. Morphine vs methadone treatment for infants with neonatal abstinence syndrome. J Pediatr. 2018;203:185–189. doi:10.1016/j.jpeds.2018.07.061.
194. Young JL, Martin PR. Treatment of opioid dependence in the setting of pregnancy. Psychiatr Clin North Am. 2012;35(2):441–460. doi:10.1016/j.psc.2012.03.008.
195. Wilder CM, Winhusen T. Pharmacological management of opioid use disorder in pregnant women. CNS Drugs. 2015;29(8):625–636. doi:10.1007/s40263-015-0273-8.
196. Substance Abuse and Mental Health Services Administration. Federal Guidelines for Opioid Treatment Programs. HHS Publication No. (SMA) PEP15-FEDGUIDEOTP. Rockville, MD: SAMHSA; 2015. https://store.samhsa.gov/system/files/pep15-fedguideotp.pdf. Accessed August 10, 2019.
197. Amato L, Minozzi S, Vecchi S, Davoli M, Perucci CA. An overview of Cochrane systematic reviews of pharmacological and psychosocial treatment of opioid dependence. Background paper for the meeting “1st Consultation on Technical Guidelines for Treatment of Opioid Dependence.” Geneva, Switzerland: World Health Organization; November, 1–4, 2005. https://www.who.int/substance_abuse/activities/overview_of_cochrane_systematic_reviews.pdf. Accessed August 10, 2019.
198. World Health Organization. Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. Geneva, Switzerland: WHO; 2009. https://www.who.int/substance_abuse/publications/opioid_dependence_guidelines.pdf. Accessed August 10, 2019.
199. Andrilla CHA, Moore TE, Patterson DG, Larson EH. Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5-year update. J Rural Heal. 2019;35(1):108–112. doi:10.1111/jrh.12307.
200. Ghertner R. U.S. trends in the supply of providers with a waiver to prescribe buprenorphine for opioid use disorder in 2016 and 2018. Drug Alcohol Depend. 2019;204(1):107527. doi:10.1016/j.drugalcdep.2019.06.029.
201. Sigmon SC. The untapped potential of office-based buprenorphine treatment. JAMA Psychiatry. 2015;72(4):395–396. doi:10.1001/jamapsychiatry.2014.2421.
202. Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105(8):e55–e63. doi:10.2105/AJPH.2015.302664.
203. Thomas CP, Doyle E, Kreiner PW, et al. Prescribing patterns of buprenorphine waivered physicians. Drug Alcohol Depend. 2017;181:213–218. doi:10.1016/j.drugalcdep.2017.10.002.
204. National Institute on Drug Abuse. Drugs, Brains, and Behavior: The Science of Addiction. NIH Publication No. 18-DA-5605. Washington, DC: National Institues of Health; 2007. https://d14rmgtrwzf5a.cloudfront.net/sites/default/files/soa.pdf. Revised 2008, 2010, 2014, 2018. Accessed October 27, 2018.
205. Midmer D, Kahan M, Wilson L. Medical students’ experiences with addicted patients: a web-based survey. Subst Abus. 2008;29(1):25–32. doi:10.1300/J465v29n01_04.
206. American Society of Addiction Medicine. Public Policy Statement on the Addiction Medicine Physician Participation in and Leadership of Multidisciplinary Care Teams. Chevy Chase, MD: ASAM; 2016. https://www.asam.org/docs/default-source/public-policy-statements/multidisciplinary-care-teams-final-jan-2016.pdf. Accessed January 16, 2019.
207. Vestal C. Nurse licensing laws block treatment for opioid addiction. Stateline, an initiative of The Pew Charitable Trusts. April 21, 2017. http://www.pewtrusts.org/en/research-and-analysis/blogs/stateline/2017/04/21/nurse-licensing-laws-block-treatment-for-opioid-addiction. Accessed August 10, 2019.
208. Polydorou S, Gunderson EW, Levin FR. Training physicians to treat substance use disorders. Curr Psychiatry Rep. 2008;10(5):399–404. doi:10.1007/s11920-008-0064-8.
209. Wakeman SE, Baggett M V, Pham-Kanter G, Campbell EG. Internal medicine residents’ training in substance use disorders: a survey of the quality of instruction and residents’ self-perceived preparedness to diagnose and treat addiction. Subst Abus. 2013;34(4):363–370. doi:10.1080/08897077.2013.797540.
210. Yoast RA, Filstead WJ, Wilford BB, Hayashi S, Reenan J, Epstein J. Teaching about substance abuse. Virtual Mentor. 2008;10(1):21–29. doi:10.1001/virtualmentor.2008.10.1.medu1-0801.
211. Grant BF, Saha TD, Ruan WJ, et al. Epidemiology of DSM-5 drug use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III. JAMA Psychiatry. 2016;73(1):39–47. doi:10.1001/jamapsychiatry.2015.2132.
212. Gunderson EW, Fiellin DA, Levin FR, Sullivan LE, Kleber HD. Evaluation of a combined online and in person training in the use of buprenorphine. Subst Abus. 2006;27(3):39–45. doi:10.1300/J465v27n03_06.
213. Weber EM. Failure of physicians to prescribe pharmacotherapies for addiction: regulatory restrictions and physician resistance. J Health Care L & Pol’y. 2010;13(1):49–76. https://pdfs.semanticscholar.org/da98/9a103ed577a89a4e76d03242bd617759d0bb.pdf. Accessed August 10, 2019.
214. Voon P, Karamouzian M, Kerr T. Chronic pain and opioid misuse: a review of reviews. Subst Abuse Treat Prev Policy. 2017;12(1):36. doi:10.1186/s13011-017-0120-7.
215. Ross S, Peselow E. Co-occurring psychotic and addictive disorders: neurobiology and diagnosis. Clin Neuropharmacol. 2012;35(5):235–243. doi:10.1097/WNF.0b013e318261e193.
216. Tanner TB, Wilhelm SE, Rossie KM, Metcalf MP. Web-based SBIRT skills training for health professional students and primary care providers. Subst Abus. 2012;33(3):316–320. doi:10.1080/08897077.2011.640151.
217. Egan JE, Casadonte P, Gartenmann T, et al. The Physician Clinical Support System–Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment. J Gen Intern Med. 2010;25(9):936–941. doi:10.1007/s11606-010-1377-y.
218. Harris AHS, Bowe T, Hagedorn H, et al. Multifaceted academic detailing program to increase pharmacotherapy for alcohol use disorder: interrupted time series evaluation of effectiveness. Addict Sci Clin Pract. 2016;11(1):15. doi:10.1186/s13722-016-0063-8.
219. Stein BD, Pacula RL, Gordon AJ, et al. Where is buprenorphine dispensed to treat opioid use disorders? The role of private offices, opioid treatment programs, and substance abuse treatment facilities in urban and rural counties. Milbank Q. 2015;93(3):561–583. doi:10.1111/1468-0009.12137.
220. Sullivan LE, Fiellin DA. Office-based buprenorphine for patients with opioid dependence. Ann Intern Med. 2008;148(9):662–670. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3694223/. Accessed August 10, 2019.
221. McCarty D, Rieckmann T, Baker RL, McConnell KJ. The perceived impact of 42 CFR Part 2 on coordination and integration of care: a qualitative analysis. Psychiatr Serv. 2017;68(3):245–249. doi:10.1176/appi.ps.201600138.
222. Uses and disclosures to carry out treatment, payment, or health care operations, 45 CFR §164.506(c)(2).
223. Permitted uses and disclosures: exchange for treatment [fact sheet]. Washington, DC: Office of the National Coordinator for Health Information Technology and Office for Civil Rights, US Department of Health and Human Services; January 2016. https://www.hhs.gov/sites/default/files/exchange_treatment.pdf. Accessed October 23, 2018.
224. Final rule: 42 CFR Part 2, confidentiality of substance use disorder patient records. American Psychiatric Association website. https://www.psychiatry.org/psychiatrists/practice/practice-management/hipaa/42-cfr-part-2. Accessed August 10, 2019.
225. D’Onofrio G, Chawarski MC, O’Connor PG, et al. Emergency department–initiated buprenorphine for opioid dependence with continuation in primary care: outcomes during and after intervention. J Gen Intern Med. 2017;32(6):660–666. doi:10.1007/s11606-017-3993-2.
226. Liebschutz JM, Crooks D, Herman D, et al. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. JAMA Intern Med. 2014;174(8):1369–1376. doi:10.1001/jamainternmed.2014.2556.
227. Administering or dispensing of narcotic drugs, 21 CFR §1306.07(b).
228. Huhn AS, Dunn KE. Why aren’t physicians prescribing more buprenorphine? J Subst Abuse Treat. 2017;78:1–7. doi:10.1016/j.jsat.2017.04.005.
229. Saxon AJ, McCarty D. Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs. Pharmacol Ther. 2005;108(1):119–128. doi:10.1016/j.pharmthera.2005.06.014.
230. Hutchinson E, Catlin M, Andrilla CH, Baldwin LM, Rosenblatt RA. Barriers to primary care physicians prescribing buprenorphine. Ann Fam Med. 2014;12(2):128–133. doi:10.1370/afm.1595.
231. Furst RT. Diffusion and diversion of suboxone: an exploration of illicit street opioid selling. J Addict Dis. 2014;33(3):177–186. doi:10.1080/10550887.2014.950030.
232. Lofwall MR, Walsh SL. A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. J Addict Med. 2014;8(5):315–326. doi:10.1097/ADM.0000000000000045.
233. Kissin W, McLeod C, Sonnefeld J, Stanton A. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. J Addict Dis. 2006;25(4):91–103. doi:10.1300/J069v25n04_09.
234. Alderks CE. Trends in the use of methadone and buprenorphine at substance abuse treatment facilities: 2003 to 2011. In: The CBHSQ Report. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2013. https://www.ncbi.nlm.nih.gov/books/NBK384659. Accessed August 10, 2019.
235. Knudsen HK, Abraham AJ, Roman PM. Adoption and implementation of medications in addiction treatment programs. J Addict Med. 2011;5(1):21–27. doi:10.1097/ADM.0b013e3181d41ddb.
236. Ducharme LJ, Knudsen HK, Roman PM, Johnson JA. Innovation adoption in substance abuse treatment: exposure, trialability, and the Clinical Trials Network. J Subst Abuse Treat. 2007;32(4):321–329. doi:10.1016/j.jsat.2006.05.021.
237. Rieckmann T, Abraham A, Zwick J, Rasplica C, McCarty D. A longitudinal study of state strategies and policies to accelerate evidence-based practices in the context of systems transformation. Health Serv Res. 2015;50(4):1125–1145. doi:10.1111/1475-6773.12273.
238. Substance Abuse and Mental Health Services Administration. Medicaid Handbook: Interface with Behavioral Health Services. HHS Publication No. SMA-13-4773. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2013. https://store.samhsa.gov/system/files/sma13-4773_mod7.pdf Accessed September 17, 2018.
239. Kermack A, Flannery M, Tofighi B, McNeely J, Lee JD. Buprenorphine prescribing practice trends and attitudes among New York providers. J Subst Abuse Treat. 2017;74:1–6. doi:10.1016/j.jsat.2016.10.005.
240. Clark RE, Baxter JD, Barton BA, Aweh G, O’Connell E, Fisher WH. The impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts Medicaid beneficiaries with opioid dependence. Health Serv Res. 2014;49(6):1964–1979. doi:10.1111/1475-6773.12201.
241. Mark TL, Lubran R, McCance-Katz EF, Chalk M, Richardson J. Medicaid coverage of medications to treat alcohol and opioid dependence. J Subst Abuse Treat. 2015;55:1–5. doi:10.1016/j.jsat.2015.04.009.
242. Reif S, Horgan CM, Hodgkin D, Matteucci AM, Creedon TB, Stewart MT. Access to addiction pharmacotherapy in private health plans. J Subst Abus Treat. 2016;66:23–29. doi:10.1016/j.jsat.2016.03.001.
243. Becerra, X. Prior authorization requirements for medication-assisted treatment of opioid use disorder [letter]. February 14, 2019. Sacramento: State of California, Office of the Attorney General. https://oag.ca.gov/system/files/attachments/press-docs/matletter.pdf. Accessed August 10, 2019.
244. McAneny B. Landmark deal on medication-assisted treatment a model for nation. Leadership Viewpoints. American Medical Association (AMA) website. January 7, 2019. https://www.ama-assn.org/advocacy/leadership-viewpoints/landmark-deal-medication-assisted-treatment-model-nation. Accessed January 16, 2019.
245. Clark RE, Samnaliev M, Baxter JD, Leung GY. The evidence doesn’t justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Aff (Millwood). 2011;30(8):1425–1433. doi:10.1377/hlthaff.2010.0532.
246. Behavioral health services. Medicaid.gov. Centers for Medicare and Medicaid Services. https://www.medicaid.gov/medicaid/benefits/bhs/index.html. Accessed September 17, 2018.
247. Bowling B, Newman D, White C, Wood A, Coustasse A. Provider reimbursement following the Affordable Care Act. Paper presented at: Business and Health Administration Association Annual Conference; March 22–24, 2017; Chicago, IL. http://mds.marshall.edu/mgmt_faculty/174. Accessed August 10, 2019.
248. The Psychiatric Shortage: Causes and Solutions. Washington, DC: National Council Medical Director Institute; 2017. https://www.thenationalcouncil.org/wp-content/uploads/2017/03/Psychiatric-Shortage_National-Council-.pdf. Accessed August 10, 2019.
249. Hinde J, Hayes J, Mark T, Bernstein S, Karon SL. State and Local Policy Levers for Increasing Treatment and Recovery Capacity to Address the Opioid Epidemic: Final Report. Washington, DC: Office of the Assistant Secretary for Planning and Evaluation, US Department of Health and Human Services; 2017. https://aspe.hhs.gov/basic-report/state-and-local-policy-levers-increasing-treatment-and-recovery-capacity-address-opioid-epidemic-final-report. Accessed August 10, 2019.
250. Drug courts [fact sheet]. Washington, DC: US Department of Justice, Office of Justice Programs; May 2018. https://www.ncjrs.gov/pdffiles1/nij/238527.pdf. Accessed July 11, 2018.
251. Supreme Court of the State of Florida. Florida Adult Drug Court Best Practice Standards. Tallahassee, FL: Florida State Courts; 2017. https://www.flcourts.org/content/download/217042/1968198/Florida_Adult_Drug_Court_Standards_I-X.pdf. Accessed May 29, 2019.
252. National Association of Drug Court Professionals’ Drug Court Standards Committee. Defining Drug Courts: The Key Components. Drug Courts Resource Series. Washington, DC: Bureau of Justice Assistance; 2004. https://www.ncjrs.gov/pdffiles1/bja/205621.pdf. Accessed May 29, 2019.
253. Public policy statement on medical ethics with annotations applicable to addiction medicine background. Rockville, MD: American Society of Addiction Medicine; January 23, 2019. https://www.asam.org/docs/default-source/public-policy-statements/public-policy-statement-on-medical-ethicsa98c289472bc604ca5b7ff000030b21a.pdf. Accessed February 20, 2019.
254. IL Staff. AG touts benefits of incarcerating drug offenders to help end cycle of addiction. Indiana Lawyer. June 9, 2017. https://www.theindianalawyer.com/articles/43943-ag-touts-benefits-of-incarcerating-drug-offenders-to-help-end-cycle-of-addiction. Accessed August 10, 2019.
255. Ettner SL, Huang D, Evans E, et al. Benefit-cost in the California treatment outcome project: does substance abuse treatment “pay for itself”? Health Serv Res. 2006;41(1):192–213. doi:10.1111/j.1475-6773.2005.00466.x.
256. Marlowe DB. Integrating substance abuse treatment and criminal justice supervision. Sci Pract Perspect. 2003;2(1):4–14. http://www.ncbi.nlm.nih.gov/pubmed/18552716. Accessed August 5, 2018.
257. Green TC, Clarke J, Brinkley-Rubinstein L, et al. Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system. JAMA Psychiatry. 2018;75(4):405–407. doi:10.1001/jamapsychiatry.2017.4614.
258. Nunn A, Zaller N, Dickman S, Trimbur C, Nijhawan A, Rich JD. Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey. Drug Alcohol Depend. 2009;105(1–2):83–88. doi:10.1016/j.drugalcdep.2009.06.015.
259. Moore KE, Roberts W, Reid HH, Smith KMZ, Oberleitner LMS, McKee SA. Effectiveness of medication assisted treatment for opioid use in prison and jail settings: a meta-analysis and systematic review. J Subst Abuse Treat. 2019;99:32–43. doi:10.1016/j.jsat.2018.12.003.
260. Hora PF, Stalcup T. Drug treatment courts in the twenty-first century: the evolution of the revolution in problem-solving courts. Georgia Law Rev. 2008;42:717–811. http://ndcrc.org/wp-content/uploads/2017/05/hora-stalcup.pdf. Accessed August 10, 2019.
261. Miller EJ. Embracing addiction: drug courts and the false promise of judicial interventionism. Ohio State Law J. 2004;65:1479–1576. https://pdfs.semanticscholar.org/e302/c28c46fbf0f738fa30a604dc0b7c7d61d965.pdf. Accessed August 10, 2019.
262. Matusow H, Dickman SL, Rich JD, et al. Medication assisted treatment in US drug courts: results from a nationwide survey of availability, barriers, and attitudes. J Subst Abuse Treat. 2013;44(5):473–480. doi:10.1016/j.jsat.2012.10.004.
263. Krawczyk N, Picher CE, Feder KA, Saloner B. Only one in twenty justice-referred adults in specialty treatment for opioid use receive methadone or buprenorphine. Health Aff (Millwood). 2017;36(12):2046–2053. doi:10.1377/hlthaff.2017.0890.
264. Monico LB, Mitchell SG, Gryczynski J, et al. Prior experience with non-prescribed buprenorphine: role in treatment entry and retention. J Subst Abuse Treat. 2015;57:57–62. doi:10.1016/j.jsat.2015.04.010.
265. Lofwall MR, Havens JR. Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine. Drug Alcohol Depend. 2012;126(3):379–383. doi:10.1016/j.drugalcdep.2012.05.025.
266. Carroll JJ, Rich JD, Green TC. The more things change: buprenorphine/naloxone diversion continues while treatment remains inaccessible. J Addict Med. 2018;12(6):459–465. doi:10.1097/ADM.0000000000000436.
267. Stöver H. Barriers to opioid substitution treatment access, entry, and retention: a survey of opioid users, patients in treatment, and treating and non-treating physicians. Eur Addict Res. 2011;17(1):44–54. doi:10.1159/000320576.
268. Gallas EM. Endorsing religion: drug courts and the 12-step recovery support program. Am Univ Law Rev. 2004;53(5):1063–1101. http://digitalcommons.wcl.american.edu/aulr/vol53/iss5/3. Accessed August 10, 2019.
269. Nordstrom BR, Marlowe DB. Medication-Assisted Treatment for Opioid Use Disorders in Drug Courts. Alexandria, VA: National Drug Court Institute; 2016. Drug Court Practioner Fact Sheet 11(2). https://www.ndci.org/wp-content/uploads/2019/01/mat_fact_sheet-1.pdf. Accessed July 16, 2018.
270. Smith v Aroostook County, Docket No. 1:18-cv-352-NT (D. Me. 2019), aff’d, No. 19-1340, (1st Cir. 2019). https://ecf.med.uscourts.gov/docpub/09102401220. Accessed August 10, 2019.
271. Eickelberg C. Probation officers should never direct medical care for people with OUD. Filter Magazine. June 6, 2019. https://filtermag.org/2019/06/06/probation-officers-should-never-direct-medical-care-for-people-with-oud/amp. Accessed August 10, 2019.
272. An act relating to drug treatment, SB 910, 80th Leg Assem, Reg Sess, (Or 2019). https://olis.leg.state.or.us/liz/2019R1/Downloads/MeasureDocument/SB910/Enrolled. Accessed June 18, 2019.
273. Andraka-Christou B, Gabriel M, Madeira J, Silverman RD. Court personnel attitudes towards medications for opioid use disorder: a state-wide survey. J. Subst Abuse Treat. 2019;104:72–82. doi:10.1016/j.jsat.2019.06.011.
274. Davies J. White House takes important first step toward fixing broken drug court system. Drug Policy Alliance Blog. February 5, 2015. http://www.drugpolicy.org/blog/white-house-takes-important-first-step-toward-fixing-broken-drug-court-system. Accessed August 10, 2019.
275. Allen RS, Olson BD. Predicting attrition in the treatment of substance use disorders. Int J Ment Health Addict. 2016;14(5):728–742. https://link.springer.com/article/10.1007/s11469-015-9602-x. Accessed August 10, 2019.
276. Patient Protection and Affordable Care Act of 2010, Pub L No. 111-148, 124 Stat 119.
277. Kresina TF. Medication assisted treatment of drug abuse and dependence: global availability and utilization. Recent Pat Antiinfect Drug Discov. 2007;2(1):79–86. doi:10.2174/157489107779561652.
278. Ysa T, Colom J, Abareda A, Ramon A, Carrion M, Segura L. Governance of Addictions: European Public Policies. Oxford, UK: Oxford University Press; 2014.
279. Chatwin C. Multi-level governance: the way forward for European illicit drug policy? Int J Drug Policy. 2007;18(6):494–502. doi:10.1016/j.drugpo.2006.12.005.
280. Best practice portal. European Monitoring Centre for Drugs and Drug Addiction website. http://www.emcdda.europa.eu/best-practice_en. Accessed September 20, 2018.
281. Laqueur H. Uses and abuses of drug decriminalization in Portugal. Law Soc Inq. 2015;40(3):746–781. doi:10.1111/lsi.12104.
282. Portugal Law 15/93 of January 22, 1993, Chapter IV, Article 40–41.
283. Portugal Law 30/2000 of November 29, 2000, Art 2. (Entered into force July 2001).
284. Nagin DS. Deterrence in the twenty-first century. Crime and Justice. 2013;42(1):199–263. doi:10.1086/670398.
285. National Institute of Justice. Five things about deterrence [fact sheet]. NCJ 247350. Washginton, DC: US Department of Justice, Office of Justice Programs; 2016. https://www.ncjrs.gov/pdffiles1/nij/247350.pdf. Accessed August 10, 2019.
286. Messaadi N, Pansu A, Cohen O, Cottencin O. Pharmacists’ role in the continued care of patients under opiate substitution treatment. Therapie. 2013;68(6):393–400. doi:10.2515/therapie/2013059.
287. Guillou Landreat M, Rozaire C, Guillet JY, Victorri Vigneau C, Le Reste JY, Grall Bronnec M. French experience with buprenorphine: do physicians follow the guidelines? PLoS One. 2015;10(10):e0137708. doi:10.1371/journal.pone.0137708.
288. Feroni I, Peretti-Watel P, Masut A, Coudert C, Paraponaris A, Obadia Y. French general practitioners’ prescribing high-dosage buprenorphine maintenance treatment: is the existing training (good) enough? Addict Behav. 2005;30(1):187–191. doi:10.1016/j.addbeh.2004.04.019.
289. Moatti JP, Souville M, Escaffre N, Obadia Y. French general practitioners’ attitudes toward maintenance drug abuse treatment with buprenorphine. Addiction. 1998;93(10):1567–1575. PMID:9926562.
290. Auriacombe M, Fatséas M, Dubernet J, Daulouède J-P, Tignol J. French field experience with buprenorphine. Am J Addict. 2004;13(S1):S17–S28. doi:10.1080=10550490490440780.
291. Jeantaud I, Harambaru F, Begaud B. Substitution treatment for opiate dependence: survey of community pharmacies in Aquitaine. Therapie. 1999;54(2):251–255.
292. Feroni I, Aubisson S, Bouhik A, et al. Collaboration between general practitioners and pharmacists in the management of patients on high-dosage buprenorphine treatment. Press Med. 2005;34(17):1213–1219.
293. Idrisov B, Murphy SM, Morrill T, Saadoun M, Lunze K, Shepard D. Implementation of methadone therapy for opioid use disorder in Russia: a modeled cost-effectiveness analysis. Subst Abuse Treat Prev Policy. 2017;12(1):4. doi:10.1186/s13011-016-0087-9.
294. Altice FL, Azbel L, Stone J, et al. The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia. Lancet. 2016;388(10050):1228–1248. doi:10.1016/S0140-6736(16)30856-X.
295. Bobrova N, Alcorn R, Rhodes T, Rughnikov I, Neifeld E, Power R. Injection drug users’ perceptions of drug treatment services and attitudes toward substitution therapy: a qualitative study in three Russian cities. J Subst Abuse Treat. 2007;33(4):373–378. doi:10.1016/j.jsat.2007.02.002.
296. MacArthur GJ, Minozzi S, Martin N, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ. 2012;345:e5945. doi:10.1136/bmj.e5945.
297. Elovich R, Drucker E. On drug treatment and social control: Russian narcology’s great leap backwards. Harm Reduct J. 2008;5(1):23. doi:10.1186/1477-7517-5-23.
298. Bachireddy C, Soule MC, Izenberg JM, Dvoryak S, Dumchev K, Altice F. Integration of health services improves multiple healthcare outcomes among HIV-infected people who inject drugs in Ukraine. Drug Alcohol Depend. 2014;134:106–114. doi:10.1016/j.drugalcdep.2013.09.020.
299. Lawrinson P, Ali R, Buavirat A, et al. Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS. Addiction. 2008;103(9):1484–1492. doi:10.1111/j.1360-0443.2008.02249.x.
300. Holt E. Fears over future of opioid substitution therapy in Crimea. Lancet. 2014;383(9923):1113. doi:10.1016/S0140-6736(14)60234-8.
301. World Health Organization. ATLAS of Substance Use Disorders: Resources for the Prevention and Treatment of Substance Use Disorders, Russian Federation. Geneva, Switzerland: WHO; 2010. http://www.who.int/substance_abuse/publications/atlas_report/profiles/russian_federation.pdf. Accessed October 11, 2018.
302. McKeganey N, Russell C, Cockayne L. Medically assisted recovery from opiate dependence within the context of the UK drug strategy: methadone and Suboxone (buprenorphine-naloxone) patients compared. J Subst Abuse Treat. 2013;44(1):97–102. doi:10.1016/j.jsat.2012.04.003.
303. Strang J, Sheridan J, Hunt C, Kerr B, Gerada C, Pringle M. The prescribing of methadone and other opioids to addicts: national survey of GPs in England and Wales. Br J Gen Pract. 2005;55(515):444–451.
304. Chutuape MA, Silverman K, Stitzer ML. Survey assessment of methadone treatment services as reinforcers. Am J Drug Alcohol Abuse. 1998;24(1):1–16. doi:10.3109/00952999809001695.
305. Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent Expert Working Group. Drug Misuse and Dependence: UK Guidelines on Clinical Management. London, England: Department of Health; 2017. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/673978/clinical_guidelines_2017.pdf. Accessed August 10, 2019.
306. Strang J, Manning V, Mayet S, Ridge G, Best D, Sheridan J. Does prescribing for opiate addiction change after national guidelines? Methadone and buprenorphine prescribing to opiate addicts by general practitioners and hospital doctors in England, 1995–2005. Addiction. 2007;102(5):761–770. doi:10.1111/j.1360-0443.2007.01762.x.
307. Harper, J. Price’s remarks on opioid treatment were unscientific and damaging, experts say. Shots: Health News from NPR. National Public Radio. May 16, 2017. https://www.npr.org/sections/health-shots/2017/05/16/528614422/prices-remarks-on-opioid-treatment-were-unscientific-and-damaging-experts-say. Accessed August 10, 2019.
308. Duke K. Exchanging expertise and constructing boundaries: the development of a transnational knowledge network around heroin-assisted treatment. Int J Drug Policy. 2016;31:56–63. doi:10.1016/j.drugpo.2015.12.004.
309. Strang J, Groshkova T, Metrebian N. New Heroin-Assisted Treatment: Recent Evidence and Current Practices of Supervised Injectable Heroin Treatment in Europe and Beyond. Luxembourg: European Monitoring Centre for Drugs and Drug Addiction; 2012. doi:10.2810/50141.
310. Csete J, Kamarulzaman A, Kazatchkine M, et al. Public health and international drug policy. Lancet. 2016;387(10026):1427–1480. doi:10.1016/S0140-6736(16)00619-X.
311. Heroin assisted treatment (HAT): saving lives, improving health, reducing crime [briefing]. Bristol, England: Transform Drug Policy Foundation; 2017. https://transformdrugs.org/wp-content/uploads/2018/10/HAT-Briefing-2017.pdf. Accessed January 31, 2019.
312. Marshall BD, Milloy M-J, Wood E, Montaner JS, Kerr T. Reduction in overdose mortality after the opening of North America’s first medically supervised safer injecting facility: a retrospective population-based study. Lancet. 2011;377(9775):1429–1437. doi:10.1016/S0140-6736(10)62353-7.
313. Lawrence TB. High-stakes institutional translation: establishing North America’s first government-sanctioned supervised injection site. Acad Manag J. 2017;60(5):1771–1800. doi:10.5465/amj.2015.0714.
314. National Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington DC: National Academies Press; 2001. doi:10.17226/10027.
315. Gerteis M, Edgman-Levitan S, Daley J, Delbanco TL, eds. Through the Patient’s Eyes: Understanding and Promoting Person-Centered Care. San Fransisco, CA: John Wiley & Sons Ltd; 1993.
316. Dreifuss JA, Griffin ML, Frost K, et al. Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: results from a multisite study. Drug Alcohol Depend. 2013;131(1–2):112–118. doi:10.1016/j.drugalcdep.2012.12.010.
317. Weiss RD, Griffin ML, Potter JS, et al. Who benefits from additional drug counseling among prescription opioid-dependent patients receiving buprenorphine-naloxone and standard medical management? Drug Alcohol Depend. 2014;140:118–122. doi:10.1016/j.drugalcdep.2014.04.005.